

AUTHORS INDEX TO VOLUME 36 (2014)

- A**
Abramenko I.V., 258
Ahmadpour Baghdadabad M.R., 215
Alexandrova E.N., 85
Arslan A., 107
Artamonova A.B., 58
Atighechi S., 215
- B**
Bakurova E.M., 117
Baradaranfar M.H., 215
Bardakhivskaya K.I., 94
Barshteyn V.Y., 58
Bayraktar E., 107
Behniafard N., 215
Bezdenezhnykh N., 72
Bhanap B., 212
Bilko D.I., 112
Bilko N.M., 112
Bilous N.I., 258
Bilyk O.O., 121
Blokhin D.Yu., 241
Boichuk I., 29
Borzenko B.G., 117
Boychuk I.V., 231
Bravo I., 44
Breda E., 44
Bubnovskaya L., 271
Buchinska L.G., 121, 179, 202, 207, 262
Burlaka A.P., 179, 196
- C**
Cakmak E.A., 107
Catarino R., 44
Chekhun S.V., 179
Chekhun V.F., 94, 125, 184, 196
Cherdyntseva N.V., 144
Cherepenko E., 52
Chernichenko O.A., 276
Chumak A.A., 258
Craveiro R., 44
- D**
Dadgarnia M.H., 215
Demirag G., 134
Denisov E.V., 144
Didenko G.V., 24
Domina E.A., 236
Drukh V.M., 90
Dulesova A.Y., 144
Dumanskiy Y., 267
Dyagil I.S., 112, 258
- E**
Erenpreisa J., 219
Erturhan S., 107
Evstratieva L.M., 24, 79
- F**
Fedosova N.I., 24, 79
Filip A., 34
- G**
Gamaleia N.F., 241
Gambashidze K., 48
Gan S.Y., 170
Gerashchenko B.I., 219
Gerashchenko O.L., 17, 174
Gevorkyan L., 48
Gheewala T.M., 9
Glushchenko N.M., 207., 262
Goala P., 9
Gogebakan B., 107
Goncharova R.I., 246
Goncharuk I.V., 125
Gordiienko I.M., 2, 162
Grabovoy A.N., 184
Gumenyuk L., 271
- H**
Hinduja S., 9
Horacek J.M., 50, 252
Huna A., 219
Hussain A., 9
- I**
Igci M., 107
Igci Y.Z., 107
Istomin Y.P., 85
Iurchenko N.P., 202, 207, 262
Ivanova T.S., 58
- J**
Jain M., 157
Jain N.K., 157
Jebavy L., 50
- K**
Karakok M., 107
Karaman O.M., 24, 79
Karesova I., 252
Kasetty S., 157
Kashuba E., 34
Kemal Y., 134
Khan S., 9, 157
Khetsuriani M.R., 174
Khomutov E., 267
Khranovska N., 17
Khristenko K.Y., 144
Kiselev V.I., 90
Kolesnik D.L., 29, 231
Kovalevska L.M., 2, 162
Kovelskaya A., 271
Krasny S.A., 246
Kravchenko O.O., 191
Krupodorova T.A., 58
- Kudryavets Y., 72
Kuiava L.M., 241
Kulik G., 226
Kupsa T., 50, 252
Kurtenkov O.A., 38
Kut E., 134
Kuznetsov I.N., 90
- L**
Lisovenko G.S., 24, 79
Litviakov N.V., 144
Lozovska Y.V., 196
Lukyanova N.Y., 125, 179, 184, 196
Lykhova O., 72
- M**
Martina Z.V., 258
Maslenny V.M., 94
Matviyenko A., 267
Medeiros R., 44
Melnikov O.R., 29
Mikhailenko V.M., 236
Mints M., 67
Mirvakili S.A., 215
Miura K., 241
Muyzhnek E.L., 90
- N**
Naleskina L.A., 196, 271
Nesina I.P., 202, 207
Nespryadko S.V., 125, 202
Niedzwiecki A., 212
Nikolaenko-Kamysheva T.P., 101
Nikolaev V.G., 94
- O**
Osharin V.V., 85
Osinsky D., 271
Ostapchenko L.I., 191
- P**
Paltsev M.A., 90
Pande N.T., 121
Pchelintseva O.I., 90
Pejovic T., 121
Perekhrestenko T.P., 112
Perelmutter V.M., 144
Philchenkov A.A., 241
Pogrebnoy P.V., 17, 174
Polishchuk L.A., 138
Polunin G.E., 117
Polyakov S.L., 246
Posokhova K.A., 94
Potebnia H.P., 24, 79
Proskurnya L.A., 207
Pushkarev V., 17
Pyaskovskaya O.N., 29, 231
Pylypchuk O.P., 236

R

Rath M., 212
 Rolevich A.I., 246
 Roomi M.W., 212
 Roomi N.W., 212

S

Sakalo A.V., 276
 Sakalo V.S., 276
 Semesiuk N., 72
 Sergejev B.L., 38
 Shah K., 9
 Sharma C., 9
 Shatova O.P., 117
 Sheikhha M.H., 215
 Shevchuk O.O., 94
 Shevchuk V., 34
 Shevchuk Z., 34
 Shishko E.D., 241
 Shlapatska L.M., 2, 162
 Shlyakhovenko V.A., 58
 Shton I.O., 241
 Shvets Y.V., 179
 Sidorenko A.S., 94
 Sidorenko S.P., 2, 162
 Skachkova O., 17

Smal M.P., 246
 Smorodin E.P., 38
 Soares S., 44
 Sokur O.V., 191
 Soldatkina M.A., 17, 174
 Solyanik G.I., 29, 231
 Sorokina L.V., 29
 Souchelnytskyi S., 67
 Stashkevych M., 267
 Svintsitsky V.S., 125, 184
 Symchych T.V., 79

T

Tan E.L., 170
 Tan J.K., 170
 Tarasova T.O., 184
 Teker F., 134
 Telegeev G.D., 52, 138
 Tkalia I.G., 125, 184
 Todor I.N., 184, 196
 Trachevsky V., 271
 Tymoshenko M.O., 191
 Tzerkovsky D.A., 85

U

Ulasli M., 107

V

Vas A.J., 9
 Vasatova M., 50, 252
 Voeykova I.M., 24, 79
 Vorobyova L.I., 125, 184
 Vozmitel M.A., 85
 Vtorushin S.V., 144

Y

Yakovlev P.G., 276
 Yilmaz B., 134
 Yucel I., 134
 Yudina O.Y., 24
 Yushko L.A., 94

Z

Zak P., 50, 252
 Zavelevich M.P., 241
 Zavyalova M.V., 144
 Zhaleiko I.O., 112
 Zhuravel O.V., 17, 174
 Zhylchuk V., 72
 Zhylchuk Y.V., 276
 Zinkovych I., 267
 Zsolt A., 276
 Zuikov S.A., 117

SUBJECT INDEX TO VOLUME 36 (2014)

- 3,3-diindolylmethane, 90
 5-fluorouracil, 267
 α -acidic glycoprotein, 101
- A**
- ABC-transporters, 144
 Actinic keratosis, 34
 Activity of NADPH-oxidase, 196
 Acute myeloid leukemia, 50, 252
 Adhesion molecules, 50, 252
 Age, 117
 Agonist of gonadotropin-releasing hormone triptorelin, 184
 Akt/PKB, 162
 Anchorage-independent growth, 17
 Aneuploidy, 219
 Antiangiogenic therapy, 85
 Anticancer activity, 90
 Anticancer substances, 58
 Anti-GalNAc-beta, 38
 Antioxidant enzymes, 29
 Antioxidant system, 196
 Antioxidants, 117
 Apoptosis, 2, 170, 226, 231, 241
 Apoptosis-controlling genes, 144
 Ascites transplantable ovarian tumor, 184
 Ascorbic acid, 236
- B**
- B-16 melanoma, 24
 Basal subtype, 179
 Bax, 9
- BCR, 162
 Bcr-Abl, 138
 Bevacizumab, 85
 Bikunin, 107
 Bioavailability, 90
 Biochip array, 50, 252
 Bladder cancer, 246
 B-lymphoblastoid cell lines, 2, 162
 Bone marrow, 72
 Bone mineral density, 276
 B-Raf, 17
 Breast cancer, 67, 72, 179, 219
 Busulfan, 112
- C**
- C-Abl, 138
 Cancer cell, 52
 Cancers of the female reproductive system, 207
 Carbon enterosorbents, 94
 Carcinogenesis, 48
 CCNA1, 170
 CD150, 2, 162
 CD1A, 34
 CD207, 34
 CD40, 2, 162
 CD8⁺ T-lymphocytes, 262
 CD95, 2
 CDK2, 170
 Ce6CPPPS, 85
 Cell culture in vitro, 112
 Cell cycle, 17
 Cell lines, 179
- CEP-specific antibodies, 79
 Ceruloplasmin, 196
 Chemokine, 138
 Chicken embryo proteins anticancer activity, 79
 Chromosomal aberrations, 202, 236
 Chronic lymphocytic leukemia, 258
 Chronic myeloid leukemia, 112
 Circulating tumor cells, 52
 Circulating tumor DNA, 52
 Cisplatin, 9
 C-Jun, 191
 Co-cultivation, 72
 Colorectal cancer, 117
 Combination, 9
 Combinatorial treatment, 67
 Co-mutagens, 236
 CXCL12, 138
 CXCR4, 138
 Cyclin D1, 9
 Cytokines, 50, 252
 Cytostatic, 184
- D**
- Depth of invasion, 262
 Dichloroacetate, 231
 DNA content analysis, 219
 DNA histogram, 219
- E**
- E-cadherin, 174
 Effectors of anticancer defence, 24
 EGF, 67

- Ehrlich carcinoma, 79
 Endometrial cancer, 202, 262
 Eosinophils, 157
 Epithelial-mesenchymal transition, 72
 ERK1/2, 162
 Erythrocyte, 117
 Estrogen, 125
 Extracts, 58
- F**
 Fanconi anemia, 212
 Ferritin, 179
FGFR3 mutation, 246
 Flow cytometry, 219
 FOXP3⁺ tumor cells, 262
 “Free iron”, 179
 “Free iron” complexes, 196
- G**
 Gastric adenocarcinoma, 267
 Gastric cancer, 38, 191, 271
 Gastrointestinal stromal tumor, 134
 Genetic contribution, 207
 Genetic polymorphisms, 44
 Glioma C6, 85, 231
 Glutathione system, 144
 Glutathione-dependent enzymes, 29
 Glycan-polyacrylamide, 38
 Guerin carcinoma, 196
- H**
 Head and neck squamous neoplasia, 157
 Hidden chromosomal instability, 202
 High risk of ovarian cancer, 121
 Hormonal receptor status, 125
 Hormone therapy, 276
 Human beta-defensin-2, 17, 174
 Human papillomavirus (HPV), 121, 215
 Hydroxycarbamide, 112
 Hydroxyethylthiamine diphosphate, 48
 Hyperoxia, 231
 Hypertension, 134
 Hypoxia, 231, 271
- I**
 Image cytometry, 219
 Imatinib, 112
 Immunotoxicity, 24
 Information resource, 207
 Inhibitor of aromatase exemestane, 184
 Intratumoral CD4⁺, 262
 Intratumoral FOXP3⁺ lymphocytes, 262
 Ionizing radiation, 236
- L**
 Langerhans cell, 34
 Leukemia cells, 241
 Lewis lung carcinoma, 79
 Lewis lung carcinoma variants, 29
 Lipid peroxidation, 29
 Lipoic acid amide, 48
 Liquid biopsy, 52
 LNCaP cell line, 90
 L-PAM, 94
 Luminal subtype, 179
- M**
 Malignant ovarian tumors, 125
 Matrigel invasion, 212
 Melanoma, 17
 Metallothionein-1, 196
 Microbiota, 38
 Microenvironment, 72
 MicroRNA, 170
 MiR-372, 170
 MiRNA 200b, 179
 MMP, 212
 Mucosa, 271
 Multi-drug resistance, 144, 241
 Mushrooms, 58
 Myeloproliferative neoplasms, 101
 Myelosuppression, 94
- N**
 Nasopharyngeal cancer, 44, 215
 Nasopharyngeal carcinoma, 170
 Normal mucosa, 267
 Nucleotide sequence analysis, 107
 Nucleotides, 117
 Nutrient mixture, 212
- O**
 Oestrogen, 67
 Oligoclonal IgG, 38
 Oncofetal antigens, 24
 Osteoporosis, 276
 Oxidative stress, 94, 117
 Oxidized glutathione (GSSG), 191
- P**
 P21, 44
 Para-Forssman, 38
 PARE, 52
 Pathomorphosis, 184
 Peripheral blood lymphocytes, 202
 Peripheral blood lymphocytes of donors and cancer patients, 236
 Ph, 48
 Phenotype of tumor, 125
 Photodynamic therapy, 85, 241
 Polymerase chain reaction, 215
 Polymorphonuclear neutrophils, 101
 Preclinical studies, 90
 Pretreatment, 112
 Progesterone, 125
- Prognosis, 215
 Prognostic marker, 107
 Proliferation, 17, 174
 Proliferative potential, 262
 Prostate cancer, 226, 276
 Prostate-selective therapies, 226
 PSA-activated pro-drugs, 226
 PSMA-targeting toxins, 226
- R**
 Rat, 184
 Reactive oxygen species, 29, 231
 Recurrence, 215
 Recurrent risk, 207
 Reduce glutathione (GSH), 191
 Regorafenib, 134
 Renal cell carcinoma, 107
 ROS, 179
- S**
 Sarcoma 37, 79
 Semi-quantitative RT-PCR, 107
 Serous ovarian cancer, 125
 Single nucleotide polymorphism, 258
 Skin cancer, 34
 SOD, 179
 Special stains, 157
 Survival, 184
 Synergistic, 9
 Synthetic lethality, 52
- T**
 Testosterone receptors, 125
 TGFβ, 67
 Thrombohemorrhagic complications, 101
 Thymidine phosphorylase, 267
 Thyroid cancer, 174
TP53 mutation, 246, 258
 Transcription factors, 162
 Transferrin, 196
 Tumor genotype, 246
 Tumor-associated tissue eosinophilia, 157
- V**
 Vaccinotherapy, 58
 VEGF, 184
 Viability, 17, 174
 Vimentin, 174
- W**
 Wheatgrass, 9
- X**
 X2, 38
 Xenogeneic anticancer (cancer) vaccine, 24, 79
 Xenograft model, 90
 X-linked lymphoproliferative disease type 1, 2, 162